NeuroMab™ Anti-ApoC3 BBB Shuttle Antibody(NRZP-1022-ZP3503)

Figure 1 is a graph showing the interference of ApoC3 antibodies on the binding of ApoC3 to dimyristoylphosphatidylcholine (DMPC).

ELISA microplates were coated with DMPC and incubated with ApoC3 and test anti-ApoC3 antibodies. Measure the amount of ApoC3 still attached to the plate using a biotinylated anti-ApoC3 polyclonal goat antibody following standard procedures for ELISA colorimetric assays.

Figure 2 shows the binding of ApoC3 to VLDL in the presence of anti-ApoC3 antibody.

Figure 3 is a graph showing that 14C7 and 13G7 attenuate the ability of ApoC3 to inhibit lipoprotein lipase (LPL) activity. 1

4C7, 13G7, 5E5, or 646 antibodies were incubated with lipid emulsion and purified ApoC3 protein. The production of non-esterified fatty acids (NEFA) was measured and the percentage of NEFA produced compared to that produced by ApoC3 but in the absence of anti-ApoC3 antibody was plotted.

Figure 4 is a set of graphs showing that certain anti-ApoC3 antibodies attenuate the ability of ApoC3 to inhibit very low density lipoprotein (VLDL) uptake by HepG2 cells.

Figure 5 shows antibody binding to human ApoC3 (huApoC3) or cvnomolgus monkey ApoC3 (cynoApoC3).

Figure 6 shows the postprandial triglyceride lowering effect of 5E5.

Mice receiving 3 × 10^11 AAV8-huApoC3 viral particles were administered either vehicle or 5E5 antibody. Oral doses of olive oil were given and triglyceride levels were measured over a period of time.

Figure 7 shows the postprandial triglyceride lowering effect of 5E5.

The area under curve ("AUC") was reduced by about 25% with 5E5 administration as compared to vehicle control with a p value of 0.030.

Figure 8 shows the postprandial triglyceride lowering effect of 5E5.

Serum ApoC3 levels were also measured over time.

Figure 9 shows the postprandial triglyceride lowering effect of 5E5.

5E5 antibody levels were also measured in a time course.

Figure 10 shows acceleration of ApoC3 and ApoB clearance from blood following subcutaneous injection of 5E5 antibody to mice expressing human ApoC3.

FIG is e graphed as percent difference from negative isotype control